48,830
edits
Difference between revisions of "Malignant melanoma"
Jump to navigation
Jump to search
→Assessment/reporting of margins
| Line 231: | Line 231: | ||
#*Positive margin = melanoma cell is touching ink. | #*Positive margin = melanoma cell is touching ink. | ||
#*Very close is reported as "clearance < 0.1 mm". | #*Very close is reported as "clearance < 0.1 mm". | ||
#Use [[immunostain]]s to assist the assessment of difficult cases: | #Use [[immunostain]]s to assist the assessment of difficult cases: | ||
#*MiTF is considered the preferred marker. | #*MiTF is considered the preferred marker. | ||
#*MART-1 (Melan A) is considered to overestimate melanocytes; it should ''not'' be used. | #*MART-1 (Melan A) is considered to overestimate melanocytes; it should ''not'' be used.<ref name=pmid21797920>{{Cite journal | last1 = Kim | first1 = J. | last2 = Taube | first2 = JM. | last3 = McCalmont | first3 = TH. | last4 = Glusac | first4 = EJ. | title = Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. | journal = J Cutan Pathol | volume = 38 | issue = 10 | pages = 775-9 | month = Oct | year = 2011 | doi = 10.1111/j.1600-0560.2011.01763.x | PMID = 21797920 }}</ref> | ||
#*S-100 also marks follicular dendritic cells; it is ''not'' a preferred marker. | |||
====Subtypes==== | ====Subtypes==== | ||